Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients

详细信息    查看全文

• 作者：Pascal Rischmann^a ; ^{rischmann.p@chu-toulouse.fr} ; Albert Gelet^b ; ^c ; ^d ; Benjamin Riche^c ; ^e ; Arnauld Villers^f ; Gilles Pasticier^g ; Pierre Bondil^h ; Jean-Luc Jungⁱ ; Hubert Bugel^j ; Jacques Petit^k ; Harry Toledano^l ; Sté ; phane Mallick^m ; Olivier Rouviè ; re^c ; ^d ; ⁿ ; Muriel Rabilloud^c ; ^e ; Hé ; lè ; ne Tonoli-Catez^b ; Sebastien Crouzet^b ; ^c ; ^d
• 关键词：Prostate cancer ; Focal therapy ; High-intensity focused ultrasound ; Hemiablation ; Prospective trial
• 刊名：European Urology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：71
• 期：2
• 页码：267-273
• 全文大小：812 K
• 卷排序：71

文摘

Up to a third of patients with localized prostate cancer have unilateral disease that may be suitable for partial treatment with hemiablation.ObjectiveTo evaluate the ability of high intensity focused ultrasound (HIFU) to achieve local control of the tumor in patients with unilateral localized prostate cancer.Design, setting, and participantsThe French Urological Association initiated a prospective IDEAL multi-institutional study (2009–2015), to evaluate HIFU-hemiablation as a primary treatment.InterventionMultiparametric magnetic resonance imaging and biopsy were used for unilateral cancer diagnosis and control, and HIFU-hemiablation.Outcome measurements and statistical analysisPrimary: absence of clinically significant cancer (CSC) on control biopsy at 1 yr (CSC: Gleason score ≥ 7 or cancer core length > 3 mm regardless of grade or > 2 positive cores). Secondary: presence of any cancer on biopsy, biochemical response, radical treatment free survival, adverse events, continence (no pad), erectile function (International Index of Erectile Function-5 ≥ 16), and quality of life (European Organization for Research and Treatment of Cancer QLQ-C28) questionnaires.Results and limitationsOne hundred and eleven patients were treated (mean age: 64.8 yr [standard deviation 6.2]; mean prostate-specific antigen: 6.2 ng/ml [standard deviation 2.6]; 68% low risk, 32% intermediate risk). Of the 101 patients with control biopsy, 96 (95%) and 94 (93%) had no CSC in the treated and contralateral lobes, respectively. Mean prostate-specific antigen at 2 yr was 2.3 ng/ml (standard deviation 1.7). The radical treatment-free survival rate at 2 years was 89% (radical treatments: six radical prostatectomies, three radiotherapies, and two HIFU). Adverse events were Grade 3 in 13%. At 12 mo continence and erectile functions were preserved in 97% and 78%. No significant decrease in quality of life score was observed at 12 mo. One limitation is the number of low-risk patients included in this study.ConclusionsAt 1 yr, HIFU-hemiablation was efficient with 95% absence of clinically significant cancer associated with low morbidity and preservation of quality of life. Radical treatment-free survival rate was 89% at 2 yr.Patient summaryThis report shows that high intensity focused ultrasound half-gland treatment of unilateral prostate cancer provides promising results with high cancer control and low morbidity.